Survey among experts on the future role of tau-PET in clinical practice and trials
(2024) In Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring 16(4).- Abstract
BACKGROUND: Recent advancements in Alzheimer's disease (AD) biomarker research and clinical trials prompt reflection on the value and consequently appropriate use of tau positron emission tomography (tau-PET) in the future. METHODS: We conducted an online survey among dementia and PET experts worldwide to investigate the anticipated future role of tau-PET in clinical practice and trials. RESULTS: Two hundred sixty-eight dementia experts, comprising 143 clinicians and 121 researchers, covering six continents participated. The vast majority (90%) fostered a positive attitude toward the added value of tau-PET in clinical practice, particularly for staging, diagnosing, monitoring, and prognostication in a cognitively impaired memory clinic... (More)
BACKGROUND: Recent advancements in Alzheimer's disease (AD) biomarker research and clinical trials prompt reflection on the value and consequently appropriate use of tau positron emission tomography (tau-PET) in the future. METHODS: We conducted an online survey among dementia and PET experts worldwide to investigate the anticipated future role of tau-PET in clinical practice and trials. RESULTS: Two hundred sixty-eight dementia experts, comprising 143 clinicians and 121 researchers, covering six continents participated. The vast majority (90%) fostered a positive attitude toward the added value of tau-PET in clinical practice, particularly for staging, diagnosing, monitoring, and prognostication in a cognitively impaired memory clinic population. Experts anticipated an important role for tau-PET for participant selection (76%–100%) and measuring endpoints (75%–97%), in both anti-amyloid and anti-tau drug trials. DISCUSSION: Our global survey study shows that dementia experts envision an important role for tau-PET in the future, both in clinical practice and in drug trials, beyond current guidelines and practices. Highlights: Dementia experts envision an important role for tau-PET in the future. Experts indicate that a tau-PET scan could influence patient management. Experts anticipate the utility of tau-PET for participant selection and endpoints in drug trials. There is a gap between the anticipated usefulness of tau-PET and current clinical practices.
(Less)
- author
- Vermeiren, Marie R. ; Calandri, Ismael L. ; van der Flier, Wiesje M. ; van de Giessen, Elsmarieke and Ossenkoppele, Rik LU
- organization
- publishing date
- 2024-10-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, positron emission tomography, tau, trials
- in
- Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
- volume
- 16
- issue
- 4
- article number
- e70033
- publisher
- Elsevier
- external identifiers
-
- pmid:39583643
- scopus:85210095171
- ISSN
- 2352-8729
- DOI
- 10.1002/dad2.70033
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2024 The Author(s). Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
- id
- 0ff3ae68-d533-42e5-92e5-d7fddf322cfb
- date added to LUP
- 2025-01-13 17:12:26
- date last changed
- 2025-07-01 07:13:34
@article{0ff3ae68-d533-42e5-92e5-d7fddf322cfb,
abstract = {{<p>BACKGROUND: Recent advancements in Alzheimer's disease (AD) biomarker research and clinical trials prompt reflection on the value and consequently appropriate use of tau positron emission tomography (tau-PET) in the future. METHODS: We conducted an online survey among dementia and PET experts worldwide to investigate the anticipated future role of tau-PET in clinical practice and trials. RESULTS: Two hundred sixty-eight dementia experts, comprising 143 clinicians and 121 researchers, covering six continents participated. The vast majority (90%) fostered a positive attitude toward the added value of tau-PET in clinical practice, particularly for staging, diagnosing, monitoring, and prognostication in a cognitively impaired memory clinic population. Experts anticipated an important role for tau-PET for participant selection (76%–100%) and measuring endpoints (75%–97%), in both anti-amyloid and anti-tau drug trials. DISCUSSION: Our global survey study shows that dementia experts envision an important role for tau-PET in the future, both in clinical practice and in drug trials, beyond current guidelines and practices. Highlights: Dementia experts envision an important role for tau-PET in the future. Experts indicate that a tau-PET scan could influence patient management. Experts anticipate the utility of tau-PET for participant selection and endpoints in drug trials. There is a gap between the anticipated usefulness of tau-PET and current clinical practices.</p>}},
author = {{Vermeiren, Marie R. and Calandri, Ismael L. and van der Flier, Wiesje M. and van de Giessen, Elsmarieke and Ossenkoppele, Rik}},
issn = {{2352-8729}},
keywords = {{Alzheimer's disease; positron emission tomography; tau; trials}},
language = {{eng}},
month = {{10}},
number = {{4}},
publisher = {{Elsevier}},
series = {{Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring}},
title = {{Survey among experts on the future role of tau-PET in clinical practice and trials}},
url = {{http://dx.doi.org/10.1002/dad2.70033}},
doi = {{10.1002/dad2.70033}},
volume = {{16}},
year = {{2024}},
}